Compare Prim SA with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
EUR 221 Million (Micro Cap)
15.00
NA
3.61%
-0.00
11.56%
1.67
Revenue and Profits:
Net Sales:
87 Million
(Quarterly Results - Dec 2021)
Net Profit:
7 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.63%
0%
-2.63%
6 Months
8.82%
0%
8.82%
1 Year
34.06%
0%
34.06%
2 Years
26.96%
0%
26.96%
3 Years
9.28%
0%
9.28%
4 Years
-8.48%
0%
-8.48%
5 Years
29.5%
0%
29.5%
Prim SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
16.99%
EBIT Growth (5y)
14.03%
EBIT to Interest (avg)
15.09
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
1.38
Tax Ratio
24.30%
Dividend Payout Ratio
56.66%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
256.99%
ROE (avg)
232.45%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
1.74
EV to EBIT
12.75
EV to EBITDA
8.74
EV to Capital Employed
1.74
EV to Sales
1.17
PEG Ratio
0.36
Dividend Yield
9.03%
ROCE (Latest)
13.64%
ROE (Latest)
11.56%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
216.50
197.20
9.79%
Operating Profit (PBDIT) excl Other Income
24.20
16.90
43.20%
Interest
1.00
0.40
150.00%
Exceptional Items
0.60
0.40
50.00%
Consolidate Net Profit
12.70
8.40
51.19%
Operating Profit Margin (Excl OI)
65.40%
43.40%
2.20%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 9.79% vs 17.03% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 51.19% vs -51.72% in Dec 2022
About Prim SA 
Prim SA
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






